Status:
COMPLETED
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The treatment received with sunitinib plus capecitabine could delay tumor growth longer than with treatment with capecitabine alone.
Eligibility Criteria
Inclusion
- Locally advanced or metastatic disease that can be measured. Patients with bone-only disease are also allowed to enter the study.
- Previous treatment with an anthracycline and a taxane in any setting
- Progression on first or second line regimen or adjuvant regimen if disease free interval less than 12 months
Exclusion
- History of inflammatory carcinoma if there is no other measurable disease
- More than 2 chemotherapy agents in the advanced disease setting
- Brain metastases
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
442 Patients enrolled
Trial Details
Trial ID
NCT00435409
Start Date
February 1 2007
End Date
June 1 2011
Last Update
June 26 2012
Active Locations (169)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Downey, California, United States, 90241
2
Pfizer Investigational Site
Fresno, California, United States, 93720
3
Pfizer Investigational Site
Montebello, California, United States, 90640
4
Pfizer Investigational Site
Whittier, California, United States, 90606